Cited 60 times in
Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 구자승 | - |
dc.contributor.author | 김승일 | - |
dc.contributor.author | 박병우 | - |
dc.contributor.author | 박세호 | - |
dc.contributor.author | 박형석 | - |
dc.contributor.author | 손주혁 | - |
dc.date.accessioned | 2014-12-20T16:30:12Z | - |
dc.date.available | 2014-12-20T16:30:12Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/92838 | - |
dc.description.abstract | Objective: Pathologic complete response (pCR) is the most predictive factor for patients with neoadjuvant chemotherapy and we investigated the rate of pCR according to molecular subtypes defined by immunohistochemical staining. Methods: Our subjects comprised 257 breast cancer patients who received 3 cycles of anthracycline/taxane-based neoadjuvant chemotherapy. The patients were classified into 4 subtypes: luminal A, luminal B, HER2 and triple negative. We analyzed the pCR rate and treatment outcome according to these subtypes. Results: Of a total of 257 patients, the pCR rate of luminal A, luminal B, HER2 and triple negative was 3.9, 5.0, 10.5 and 21.1%, respectively (p = 0.001). The 5-year disease-free survival of the pCR group (88.4%) was higher than that of the non-pCR group (65.6%), but it was not significant (p = 0.228). Among patients who have residual disease, the 5-year disease-free survival of luminal A, luminal B, HER2 and triple negative was 64.0, 65.7, 75.2 and 66.5%, respectively (p = 0.243). Triple negative and HER2 subtypes are more sensitive to neoadjuvant chemotherapy. Conclusion: To increase the pCR rate, type-specific approaches according to subtypes, such as an addition of trastuzumab, increasing the number of cycles or a novel regimen, should be considered. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 324~330 | - |
dc.relation.isPartOf | ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pathology (병리학) | - |
dc.contributor.googleauthor | Kim S.I. | - |
dc.contributor.googleauthor | Sohn J. | - |
dc.contributor.googleauthor | Koo J.S. | - |
dc.contributor.googleauthor | Park S.H. | - |
dc.contributor.googleauthor | Park H.S. | - |
dc.contributor.googleauthor | Park B.W. | - |
dc.identifier.doi | 10.1159/000322192 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00198 | - |
dc.contributor.localId | A00658 | - |
dc.contributor.localId | A01475 | - |
dc.contributor.localId | A01524 | - |
dc.contributor.localId | A01753 | - |
dc.contributor.localId | A01995 | - |
dc.relation.journalcode | J02416 | - |
dc.identifier.eissn | 1423-0232 | - |
dc.identifier.url | http://www.karger.com/Article/FullText/322192 | - |
dc.subject.keyword | Breast cancer | - |
dc.subject.keyword | Molecular subtype | - |
dc.subject.keyword | Neoadjuvant chemotherapy | - |
dc.subject.keyword | Pathologic complete response | - |
dc.contributor.alternativeName | Koo, Ja Seung | - |
dc.contributor.alternativeName | Kim, Seung Il | - |
dc.contributor.alternativeName | Park, Byeong Woo | - |
dc.contributor.alternativeName | Park, Se Ho | - |
dc.contributor.alternativeName | Park, Hyung Seok | - |
dc.contributor.alternativeName | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | Koo, Ja Seung | - |
dc.contributor.affiliatedAuthor | Kim, Seung Il | - |
dc.contributor.affiliatedAuthor | Park, Byeong Woo | - |
dc.contributor.affiliatedAuthor | Park, Se Ho | - |
dc.contributor.affiliatedAuthor | Park, Hyung Seok | - |
dc.contributor.affiliatedAuthor | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | 구자승 | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 79 | - |
dc.citation.number | 5-6 | - |
dc.citation.startPage | 324 | - |
dc.citation.endPage | 330 | - |
dc.identifier.bibliographicCitation | ONCOLOGY, Vol.79(5-6) : 324-330, 2011 | - |
dc.identifier.rimsid | 28788 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.